
Daraxonrasib RAS(ON) Inhibitor: Pancreatic Cancer Results
Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.
© 2026 IntuitionLabs. All rights reserved.